• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Home > News

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Screening activities in village in Guinea
Tokyo / Geneva — 25 Apr 2025
  • English
    • English
    • 日本語

DNDi has been named the recipient of the 5th prestigious Hideyo Noguchi Africa Prize in the medical services category, as announced today by the Government of Japan.  

‘This Prize is an immense honour for DNDi. We would like to sincerely thank the Prize Committee and the Government of Japan for shining a light on the millions of vulnerable and forgotten people who are killed, disabled, or impoverished each year by deadly infectious diseases – diseases that, unfortunately, remain neglected in pharmaceutical research,’ said Dr Luis Pizarro, Executive Director of DNDi. 

‘At a time of global retreat from multilateral support for global health, this recognition and support from the Government of Japan for the most neglected is both timely and deeply encouraging. We are humbly following in the footsteps of Dr Hideyo Noguchi by conducting clinical trials across the African continent and developing better treatments for diseases affecting African communities, included visceral leishmaniasis, mycetoma, sleeping sickness, cryptococcal meningitis, and river blindness,’ added Dr Pizarro. 

‘Our patients urgently need better, safer, and more field-adapted affordable medicines. Since our creation 22 years ago, we have developed and delivered 13 new treatments for neglected diseases, many of which play a significant role in disease elimination. The development of the first oral treatment for sleeping sickness, which was specifically recognized in this award, is the result of the invaluable partnerships we have built with universities, laboratories, pharmaceutical companies, and donors around the world,’ said Daisuke Imoto, DNDi Japan and Business Development Director. 

‘To tackle and ultimately eliminate neglected diseases, research and innovation are key. That is why our partnerships, which bring together Japanese and African knowledge and resources in this common endeavour, are so important. I would also like to commend the Japanese Government for its leadership in raising the profile of neglected tropical diseases in international forums, ensuring that these diseases are not forgotten and that research continues to receive the support it needs,’ concluded Daisuke Imoto. 

The Hideyo Noguchi Africa Prize was established in 2006 by the Government of Japan in honour of the Japanese medical scientist Dr Hideyo Noguchi (1876-1928), who dedicated his life to bacteriological research and died while studying yellow fever in Africa. The prize highlights fundamental medical and clinical research and celebrate the efforts of organizations and individuals tackling infectious diseases affecting primarily African communities. 

DNDi will receive the award for the medical services category, which focuses on ‘field-level medical/public health activities to combat diseases and advance public health’. The award ceremony will take place in August 2025 to coincide with the Ninth Tokyo International Conference on African Development (TICAD9).  

The Hideyo Noguchi Africa Prize is awarded every three years and is accompanied by a citation, a medal, and 100 million yen. 

About DNDi 

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected people. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, mycetoma, dengue, paediatric HIV, advanced HIV disease, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health, gender equity and gender-responsive R&D, and diseases impacted by climate change. Since its creation in 2003, DNDi has joined with public and private partners across the globe to deliver 13 new treatments, saving millions of lives.  dndi.org  

Medica contacts

For interview requests, please contact: 

  • Yoko Noda in Tokyo (Japanese/English): ynoda@dndi.org | +81 70 4465 5453 
  • Edith Magak in Nairobi (English): emagak@dndi.org | +254 780 862 049 
  • James Arkinstall in Geneva (French/English): jarkinstall@dndi.org | +41 79 392 9823 

Photo credits: Brent Stirton/Getty Images

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

Stories
14 Apr 2025

DNDi supporting a pioneering project that integrates Indigenous knowledge in the treatment of Chagas

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License